Salivary Carcinosarcoma: An Extremely Rare and Highly Aggressive Malignancy. (10th July 2019)

• Record Type: Journal Article
• Authors: Gupta, Avigeet; Koochakzadeh, Sina; Neskey, David M.; Nguyen, Shaun A.; Lentsch, Eric J.
• Is Part Of: Laryngoscope. Volume 130:Number 5(2020)
• Page Start: E335
• Page End: E339
• Publication Date: 2019-07-10
• Subjects: Carcinosarcoma -- salivary malignancies -- parotid gland -- malignant mixed tumor; Otolaryngology -- Periodicals; 617.51005
• DOI: 10.1002/lary.28183
• Languages: English
• ISSNs: 0023-852X

Abstract

Abstract : Objectives/Hypothesis: Carcinosarcomas represent a rare entity of mixed malignant tumors of the salivary gland with limited evidence regarding management strategies. We aim to demonstrate the incidence, prognostic factors, and conduct a survival analysis for this aggressive malignancy. Study Design: Retrospective database review. Methods: The Surveillance, Epidemiology, and End Results database was queried for all cases of major salivary carcinosarcoma and its incidence from 1973 to 2015 to identify 66 patients. Results: The incidence of this tumor was 0.02 cases per 1 million, with a rising number of absolute cases in the past 2 decades. The parotid gland was the most common site (78.8%) of involvement. The 5‐year overall survival was 37% and 5‐year disease‐specific survival was 62%. Surgery was most common management strategy (95.5%), with total parotidectomy and facial nerve sacrifice procedures for those with parotid disease. Radiotherapy was commonly performed (75.8%) and chemotherapy use was rare (18.2%). Patients with distant metastasis had a greater than threefold increase in mortality, and those with total parotidectomy surgery had decreased mortality. Conclusions: Carcinosarcomas of major salivary glands are extremely rare and highly aggressive tumors. We recommend prompt surgical management and postoperative radiation for this tumor with a poor prognosis. Level of Evidence: NA Laryngoscope, 130:E335–E339, 2020